116 related articles for article (PubMed ID: 15044430)
1. Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis.
Conway SP; Etherington C; Peckham DG; Brownlee KG; Whitehead A; Cunliffe H
J Antimicrob Chemother; 2004 May; 53(5):841-7. PubMed ID: 15044430
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy.
Boogaerts MA; Maertens J; Van Der Geest R; Bosly A; Michaux JM; Van Hoof A; Cleeren M; Wostenborghs R; De Beule K
Antimicrob Agents Chemother; 2001 Mar; 45(3):981-5. PubMed ID: 11181397
[TBL] [Abstract][Full Text] [Related]
3. Effects of cyclosporine a on single-dose pharmacokinetics of intravenous itraconazole in patients with hematologic malignancies.
Timmers GJ; Kessels LW; Wilhelm AJ; Veldkamp AI; Bosch TM; Beijnen JH; Huijgens PC
Ther Drug Monit; 2008 Jun; 30(3):301-5. PubMed ID: 18520601
[TBL] [Abstract][Full Text] [Related]
4. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients.
Hennig S; Waterhouse TH; Bell SC; France M; Wainwright CE; Miller H; Charles BG; Duffull SB
Br J Clin Pharmacol; 2007 Apr; 63(4):438-50. PubMed ID: 17073891
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection.
Zhao Q; Zhou H; Pesco-Koplowitz L
J Clin Pharmacol; 2001 Dec; 41(12):1319-28. PubMed ID: 11762559
[TBL] [Abstract][Full Text] [Related]
6. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS.
Caillot D; Bassaris H; McGeer A; Arthur C; Prentice HG; Seifert W; De Beule K
Clin Infect Dis; 2001 Oct; 33(8):e83-90. PubMed ID: 11550120
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
[TBL] [Abstract][Full Text] [Related]
8. Itraconazole plasma and tissue concentrations in the spiny lizard (Sceloporus sp.) following once-daily dosing.
Gamble KC; Alvarado TP; Bennett CL
J Zoo Wildl Med; 1997 Mar; 28(1):89-93. PubMed ID: 9226621
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation.
Michallet M; Persat F; Kranzhöfer N; Levron JC; Prat C; Belhabri A; Chwetzoff E; Le Moing JP; Fiere D; Piens MA
Bone Marrow Transplant; 1998 Jun; 21(12):1239-43. PubMed ID: 9674858
[TBL] [Abstract][Full Text] [Related]
10. Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats.
Boothe DM; Herring I; Calvin J; Way N; Dvorak J
Am J Vet Res; 1997 Aug; 58(8):872-7. PubMed ID: 9256973
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis.
Tejani A; Alexander S; Ettenger R; Lerner G; Zimmerman J; Kohaut E; Briscoe DM
Pediatr Transplant; 2004 Apr; 8(2):151-60. PubMed ID: 15049795
[TBL] [Abstract][Full Text] [Related]
12. Marked intra- and inter-patient variability of itraconazole steady state plasma concentrations.
Poirier JM; Berlioz F; Isnard F; Cheymol G
Therapie; 1996; 51(2):163-7. PubMed ID: 8763051
[TBL] [Abstract][Full Text] [Related]
13. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole.
Van de Velde VJ; Van Peer AP; Heykants JJ; Woestenborghs RJ; Van Rooy P; De Beule KL; Cauwenbergh GF
Pharmacotherapy; 1996; 16(3):424-8. PubMed ID: 8726601
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation.
Mouton JW; van Peer A; de Beule K; Van Vliet A; Donnelly JP; Soons PA
Antimicrob Agents Chemother; 2006 Dec; 50(12):4096-102. PubMed ID: 16982783
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetics of oral theophylline. Comparison between asthmatic and cystic fibrosis patients].
Repetto T; Marianelli L; Valenza T; Rosselli P; Messori A
Pediatr Med Chir; 1985; 7(6):823-5. PubMed ID: 3837249
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
18. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.
Boellner SW; Pennick M; Fiske K; Lyne A; Shojaei A
Pharmacotherapy; 2007 Sep; 27(9):1253-62. PubMed ID: 17723079
[TBL] [Abstract][Full Text] [Related]
20. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.
Slain D; Amsden JR; Khakoo RA; Fisher MA; Lalka D; Hobbs GR
Pharmacotherapy; 2005 Feb; 25(2):165-70. PubMed ID: 15767232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
